Virological and Preclinical Characterization of a Dendritic Cell Targeting, Integration-deficient Lentiviral Vector for Cancer Immunotherapy-Reference-Cited by-同舟云学术

Virological and Preclinical Characterization of a Dendritic Cell Targeting, Integration-deficient Lentiviral Vector for Cancer Immunotherapy

Published:2015-02 Issue:2 Volume:38 Page:41-53
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Odegard Jared M.,Kelley-Clarke Brenna,Tareen Semih U.,Campbell David J.,Flynn Patrick A.,Nicolai Christopher J.,Slough Megan M.,Vin Chintan D.,McGowan Patrick J.,Nelson Lisa T.,ter Meulen Jan,Dubensky Thomas W.,Robbins Scott H.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference8 articles.

1. Dendritic cells: master regulators of the immune response.;Mellman;Cancer Immunol Res,2013

2. Dendritic-cell-based therapeutic cancer vaccines.;Palucka;Immunity,2013

3. Immunologic basis of vaccine vectors.;Liu;Immunity,2010

4. Lentiviral vectors for anti-tumor immunotherapy.;Breckpot;Curr Gene Ther,2008

5. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells.;Wiskerchen;J Virol,1995

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through;Biomedicines;2022-01-05

2. Intratumoral expression of IL-12 from lentiviral or RNA vectors acts synergistically with TLR4 agonist (GLA) to generate anti-tumor immunological memory;PLOS ONE;2021-12-02

3. The Old and the New: Prospects for Non-Integrating Lentiviral Vector Technology;Viruses;2020-09-29

4. ZVex™, a dendritic-cell-tropic lentivector, primes protective antitumor T cell responses that are significantly boosted using heterologous vaccine modalities;Vaccine;2020-09

5. Toll-Like Receptor 4 Expression on Lymphoma Cells Is Critical for Therapeutic Activity of Intratumoral Therapy With Synthetic TLR4 Agonist Glucopyranosyl Lipid A;Frontiers in Oncology;2020-08-19